Rocio Navarro

QUBE Technology Park
Tres Cantos, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.

Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.

Journal: Oncoimmunology

Published: October 27, 2025

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation.

Journal: Frontiers in immunology

Published: September 10, 2024

Neutrophil-to-lymphocyte ratio is associated with accelerometer-measured physical activity levels in breast cancer survivors.

Neutrophil-to-lymphocyte ratio is associated with accelerometer-measured physical activity levels in breast cancer survivors.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: September 04, 2024

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Journal: Antibodies (Basel, Switzerland)

Published: January 12, 2024

Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.

Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates.

Journal: Toxicology and applied pharmacology

Published: December 20, 2023

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.

Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 16, 2023

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Journal: Oncoimmunology

Published: April 28, 2023

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer.

Journal: Oncoimmunology

Published: February 14, 2022

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.

Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity.

Journal: iScience

Published: February 04, 2022

TGF-β-induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion.

TGF-β-induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion.

Journal: Molecular oncology

Published: December 20, 2019

Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

Anti-tumoral potential of a human granulysin-based, CEA-targeted cytolytic immunotoxin.

Journal: Oncoimmunology

Published: March 19, 2019

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.

Journal: Nature communications

Published: June 05, 2018

Showing 1-12 of 19

Last Updated: 09/26/2026